The U.S. generic sterile injectable market market size is estimated at USD 17.91 billion in 2025 and is predicted to reach around USD 39.10 billion by 2034, accelerating at a CAGR of 9.15% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: US Generic Sterile Injectables Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. US Generic Sterile Injectables Market Revenue and Volume, by Product Type
8.1.1 Monoclonal Antibodies
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Cytokines
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Insulin
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Peptide Hormones
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Vaccines
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Immunoglobulin
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Blood Factors
8.1.7.1. Market Revenue and Volume Forecast
8.1.8. Antibiotics
8.1.8.1. Market Revenue and Volume Forecast
8.1.9. Others
8.1.9.1. Market Revenue and Volume Forecast
9.1. US Generic Sterile Injectables Market Revenue and Volume, by Therapeutic Application
9.1.1. Cancer
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Diabetes Therapeutic Application
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Cardiovascular Disease
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Central Nervous System
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Musculoskeletal System
9.1.5.1. Market Revenue and Volume Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Volume Forecast
10.1. US Generic Sterile Injectables Market Revenue and Volume, by Distribution Channel
10.1.1. Hospitals
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Drug Stores
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Retail Pharmacies
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast
11.1. U.S.
11.1.1. Market Revenue and Volume Forecast, by Product Type
11.1.2. Market Revenue and Volume Forecast, by Therapeutic Application
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel
12.1. Pfizer
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Mylan
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sandoz
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. 3M
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Par Pharmaceutical, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Hikma Pharmaceuticals PLC
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Gland Pharma Limited
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. CIVICA
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ascendia Pharmaceuticals
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck & Co., Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample